Table 2.
Comparison of the incidence of main drug-related AEs of grade ≥ 2 between the groups at final follow-up
| AEs | CB (n = 130) | CA (n = 134) | p-value |
|---|---|---|---|
| Thrombosis/embolism, grade ≥ 3, n (%) | 17(13.1) | 7(5.2) | 0.026*a |
| Neutropenia, grade ≥ 4, n (%) | 10(7.7) | 3(2.2) | 0.041*a |
| Febrile neutropenia, grade ≥ 3, n (%) | 16(12.3) | 6(4.5) | 0.021*a |
| Fistula, grade ≥ 2, n (%) | 8(6.2) | 9(6.7) | 0.852a |
| Fistula, grade ≥ 3, n (%) | 7(5.4) | 6(4.5) | 0.733a |
| Hypertension, grade ≥ 2, n (%) | 15(11.5) | 17(12.7) | 0.775a |
| Bleeding, grade ≥ 3, n (%) | 9(6.9) | 8(6.0) | 0.752a |
| Proteinuria, grade ≥ 3, n (%) | 11(8.5) | 15(11.2) | 0.456a |
| Pain, grade ≥ 2, n (%) | 25(19.2) | 28(20.9) | 0.736a |
*Statistically significant values.aAnalysed using the chi-square test. AEs adverse events, CB cisplatin-based chemotherapy plus bevacizumab, CA cisplatin-based chemotherapy alone, AEs adverse events